Brought to you by 
Series B raises $7.5mm for Ocugen
19 Jan 2018
Executive Summary
Ocugen Inc. (therapies for eye diseases) raised $7.5mm in its Series B financing led by Turkish pharmaco Abdi Ibrahim and JSC Lancaster Group, which were joined by two returning individual investors. The company will use the money to move its OCU100 for retinitis pigmentosa and OCU200 for wet age-related macular degeneration into the clinic.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B raises $7.5mm for Ocugen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice